Cassava Sciences, Inc. Warrant
NASDAQ: SAVAW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard Jon Barry
- Employees
- 30
- Headquarters
- Austin, United States
- IPO year
- 2024
- Market cap
- $1.4M
- Website
- https://www.cassavasciences.com
Loading SAVAW…
Loading profile data…Frequently asked questions about SAVAW
What does Cassava Sciences, Inc. Warrant (SAVAW) do?
Cassava Sciences, Inc. is a biotechnology firm currently in the clinical development stage, dedicated to discovering therapies for neurodegenerative disorders. Their key therapeutic asset is simufilam, a small molecule drug that has already completed its Phase 2b clinical evaluation. Furthermore, the company is advancing SavaDx, a diagnostic too...
Where does SAVAW trade?
Cassava Sciences, Inc. Warrant (SAVAW) trades on the NASDAQ Global Market.
What sector is SAVAW in?
Cassava Sciences, Inc. Warrant (SAVAW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cassava Sciences, Inc. Warrant?
Richard Jon Barry is the chief executive officer of Cassava Sciences, Inc. Warrant (SAVAW).
Where is Cassava Sciences, Inc. Warrant headquartered?
Cassava Sciences, Inc. Warrant is headquartered in United States.
Does SAVAW pay a dividend?
Cassava Sciences, Inc. Warrant (SAVAW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SAVAW go public?
Cassava Sciences, Inc. Warrant (SAVAW) completed its initial public offering in 2024.